B7-H3 is a transmembrane glycoprotein widely present on the cell surface of many solid tumors, and its expression rate in uroepithelial carcinoma is as high as 60-80%, and is associated with poor prognosis, making it a dual-acting target with the potential of “direct tumor killing” and “immunosuppression relief”. The gene discussed is CD276; the disease is urothelial carcinoma.